|Bid Price||-||Offer Price||-|
|Mid Price||GBX 46.59||Day Change||GBX +0.15 (0.32%)|
|Price Date||21 Nov 2017||Crown Rating|
|Shares Class||Inc.||Yield||3.70 %|
|Total Expense Ratio||1.64||Fund Size||21,300,000.00|
|Launch Date||30/03/2007||Standard Initial Charge (%)||0.00|
|Annual Management Charge (%)||1.00||Sector||IMA UK Equity Income|
|Min Investment (£)||1,000.00||Total Expense Ratio (%)||1.64|
|ISIN||GB0031616039||Min TopUp (£)||500.00|
The Fund seeks to generate income and achieve long term capital growth through active management of a diversified portfolio invested primarily in UK equities.
Steve Magill is a Senior Portfolio Manager with a focus on UK Value Equity strategies. He joined UBS Global Asset Management in 1986, originally as an investment assistant. He took a career break between 1990 and 1993 to study, returning as a UK Equity Portfolio Manager. In 2000, Steve became a Pan-European pharmaceutical research analyst, taking on the role of Deputy Head of European Research in 2007. During this period Steve also co-ordinated the Global Healthcare team. He took on his current role in 2009. Steve is a Regular Member of the CFA Society of the UK and the CFA Institute.